Oruka Therapeutics, Inc. (ORKA)

NGM – Real Time Price. Currency in USD

90.60

+3.97 (4.58%)

At close: Jun 26, 2026, 4:00 PM EDT

90.58

-0.02 (-0.02%)

After-hours: Jun 26, 2026, 7:34 PM EDT

12.06.2026

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10.06.2026

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

28.05.2026

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.

13.05.2026

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026

06.05.2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

28.04.2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.

27.04.2026

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Videos

No Data

There is no data to display

Press releases

13.05.2026

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026

06.05.2026

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

28.04.2026

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

27.04.2026

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Oruka Therapeutics, Inc. (ORKA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Videos

No Data

Press releases

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Videos

No Data

Press releases

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Search stocks

Oruka Therapeutics, Inc. (ORKA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Videos

No Data

Press releases

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade

Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript

Videos

No Data

Press releases

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering